Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Macitentan 75 mg vs 10 mg in Pulmonary Arterial Hypertension
NCT04273945Phase 3Active, not recruiting
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Jun 2020
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 42
01
Overview
A Phase 3 trial of macitentan in pulmonary arterial hypertension (PAH), sponsored by Actelion Pharmaceuticals Ltd. Started Jun 2020; status: active, not recruiting.
02
Drugs
macitentan
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT04273945.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04273945.